GH- NAS (USA) Also traded in: Germany, Mexico
Guardant Health Inc

Not Rated

Top Ranked Predictable Companies

$36.49

0.78(2.09%) Volume: 1,376,126 4:00PM EDT

Avg Vol (1m): 1,566,474

Warning! GuruFocus has detected 4 Severe Warning Signs with NAS:GH. Click here to check it out.

Market Cap : 3.72 B	Enterprise Value : 4.21 B	PE Ratio : At Loss	PB Ratio : 7.19

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

Switch to:

中文

Fundamental
- 5-Year EBITDA Growth Rate
- Altman Z-Score
- Beneish M-Score
- Book Value per Share
- Cash per Share
- Dividends per Share
- E10
- Earnings per Share (Diluted)
- EBIT per Share
- EBITDA per Share
- Enterprise Value
- EPS without NRI
- FFO per Share
- Financial Strength
- Float Percentage Of Total Shares Outstanding
- Free Cash Flow per Share
- GF Score
- GF Value Rank
- Growth Rank
- Insider Ownership
- Institutional Ownership
- Market Cap
- Momentum Rank
- Net Cash per Share
- Net Current Asset Value
- Net-Net Working Capital
- Operating Cash Flow per Share
- Owner Earnings per Share (TTM)
- Piotroski F-Score
- Predictability Rank
- Probability of Financial Distress (%)
- Profitability Rank
- Quality Rank
- Revenue per Share
- Scaled Net Operating Assets
- Short Interest
- Short Percentage of Float
- Tangible Book per Share
- Total Debt per Share
- Valuation Rank
- YoY EBITDA Growth
- YoY EPS Growth
- YoY Rev. per Sh. Growth
Valuation Ratio
- Asset Turnover
- Buyback Yield %
- Capex-to-Operating-Cash-Flow
- Capex-to-Operating-Income
- Capex-to-Revenue
- Cash Conversion Cycle
- Cash Ratio
- Cash-to-Debt
- COGS-to-Revenue
- Current Ratio
- Days Inventory
- Days Payable
- Days Sales Outstanding
- Debt-to-Asset
- Debt-to-EBITDA
- Debt-to-Equity
- Debt-to-Revenue
- Earnings Yield %
- Earnings Yield (Joel Greenblatt) %
- Effective Interest Rate on Debt %
- Equity-to-Asset
- EV-to-EBIT
- EV-to-EBITDA
- EV-to-FCF
- EV-to-Revenue
- Forward PE Ratio
- Forward Rate of Return (Yacktman) %
- Goodwill-to-Asset
- Gross-Profit-to-Asset %
- Interest Coverage
- Inventory Turnover
- Inventory-to-Revenue
- Liabilities-to-Assets
- LT-Debt-to-Total-Asset
- PB Ratio
- PE Ratio
- PE Ratio
- PE Ratio without NRI
- PEG Ratio
- Price-to-Free-Cash-Flow
- Price-to-Funds-From-Operations
- Price-to-Operating-Cash-Flow
- Price-to-Owner-Earnings
- Price-to-Tangible-Book
- PS Ratio
- Quick Ratio
- Return-on-Tangible-Asset
- Return-on-Tangible-Equity
- ROA %
- ROC %
- ROC (Joel Greenblatt) %
- ROCE %
- ROE %
- ROE % Adjusted to Book Value
- ROIC %
- Shares Buyback Ratio %
- Shiller PE Ratio
- Short Ratio
- Sloan Ratio %
- Total Payout Ratio
- Total Payout Yield %
- WACC %
Profitability
- EBITDA Margin %
- FCF Margin %
- Gross Margin %
- Net Interest Margin (Bank Only) %
- Net Margin %
- Operating Margin %
Price
- Beta
- Earnings Power Value (EPV)
- GF Value
- Graham Number
- Intrinsic Value: DCF (Earnings Based)
- Intrinsic Value: DCF (FCF Based)
- Intrinsic Value: Projected FCF
- Margin of Safety % (DCF Earnings Based)
- Median PS Value
- Peter Lynch Fair Value
- Volatility
Dividends
- 3-Year Dividend Growth Rate
- 5-Year Dividend Growth Rate
- 5-Year Yield-on-Cost %
- Dividend Payout Ratio
- Dividend Yield %
- Dividend-Payout-to-FFO
- Forward Dividend Yield %
Income Statement
- Cost of Goods Sold
- Credit Losses Provision
- Depreciation, Depletion and Amortization
- EBIT
- EBITDA
- EPS (Basic)
- EPS (Diluted)
- Fees and Other Income
- Gross Profit
- Interest Expense
- Interest Expense (Positive)
- Interest Income
- Net Income
- Net Income (Continuing Operations)
- Net Income (Discontinued Operations)
- Net Interest Income
- Net Interest Income (for Banks)
- Net Investment Income
- Net Policyholder Benefits/Claims
- Non Interest Income
- Non Operating Income
- Operating Income
- Other Expense
- Other Income (Expense)
- Other Income (Minority Interest)
- Other Noninterest Expense
- Other Operating Expense
- Policy Acquisition Expense
- Pre-Tax Income
- Preferred Dividends
- Research & Development
- Revenue
- Selling, General, & Admin. Expense
- Shares Outstanding (Basic Average)
- Shares Outstanding (Diluted Average)
- SpecialCharges
- Tax Expense
- Tax Provision
- Tax Rate %
- Total Expenses
- Total Noninterest Expense
- Total Operating Expense
- Total Premiums Earned
Balance Sheet
- Accounts Payable
- Accounts Payable & Accrued Expense
- Accounts Payable & Accrued Expense for Financial Companies
- Accounts Receivable
- Accumulated Depreciation
- Accumulated other comprehensive income (loss)
- Additional Paid-In Capital
- Allowance For Loans And Lease Losses
- Buildings And Improvements
- Cash And Cash Equivalents
- Cash and cash equivalents
- Cash, Cash Equivalents, Marketable Securities
- Common Stock
- Construction In Progress
- Current Accrued Expense
- Current Deferred Revenue
- Current Deferred Taxes Liabilities
- Deferred Policy Acquisition Costs
- DeferredTaxAndRevenue
- Equity Investments
- Fixed Maturity Investment
- Future Policy Benefits
- Goodwill
- Gross Loan
- Gross Property, Plant and Equipment
- Intangible Assets
- Inventories, Finished Goods
- Inventories, Inventories Adjustments
- Inventories, Other
- Inventories, Raw Materials & Components
- Inventories, Work In Process
- Investments And Advances
- Land And Improvements
- Loans Receivable
- Long-Term Capital Lease Obligation
- Long-Term Debt
- Long-Term Debt & Capital Lease Obligation
- Machinery, Furniture, Equipment
- Marketable Securities
- Minority Interest
- Money Market Investments
- Net Loan
- NonCurrent Deferred Liabilities
- Notes Receivable
- Other Assets for Banks
- Other Assets for Insurance Companies
- Other Current Assets
- Other Current Liabilities
- Other Current Payables
- Other Current Receivables
- Other Gross PPE
- Other Liabilities for Banks
- Other Liabilities for Insurance Companies
- Other Long Term Assets
- Other Long-Term Liabilities
- Other Stockholders Equity
- PensionAndRetirementBenefit
- Policyholder Funds
- Preferred Stock
- Property, Plant and Equipment
- Retained Earnings
- Securities & Investments
- Shares Outstanding (EOP)
- Short-Term Capital Lease Obligation
- Short-Term Debt
- Short-Term Debt & Capital Lease Obligation
- Short-term investments
- Total Assets
- Total Current Assets
- Total Current Liabilities
- Total Deposits
- Total Equity
- Total Inventories
- Total Liabilities
- Total Long-Term Assets
- Total Long-Term Liabilities
- Total Receivables
- Total Stockholders Equity
- Total Tax Payable
- Treasury Stock
- Unearned Income
- Unearned Premiums
- Unpaid Loss & Loss Reserve
Cashflow Statement
- All Taxes Paid
- Asset Impairment Charge
- Beginning Cash Position
- Capital Expenditure
- Cash Flow for Dividends
- Cash Flow from Discontinued Operations
- Cash Flow from Financing
- Cash Flow from Investing
- Cash Flow from Operations
- Cash Flow from Others
- Cash From Discontinued Investing Activities
- Cash from Discontinued Operating Activities
- Cash From Other Investing Activities
- Cash Paid for Insurance Activities
- Cash Payments
- Cash Payments for Deposits by Banks and Customers
- Cash Payments for Loans
- Cash Receipts from Deposits by Banks and Customers
- Cash Receipts from Fees and Commissions
- Cash Receipts from Loans
- Cash Receipts from Operating Activities
- Cash Receipts from Securities Related Activities
- Cash Receipts from Tax Refunds
- Cash Received from Insurance Activities
- Change In Inventory
- Change In Other Working Capital
- Change In Payables And Accrued Expense
- Change In Prepaid Assets
- Change In Receivables
- Change In Working Capital
- Deferred Tax
- Depreciation, Depletion and Amortization
- Dividends Paid
- Dividends Received
- Effect of Exchange Rate Changes
- Ending Cash Position
- FFO
- Free Cash Flow
- Interest and Commission Paid
- Interest Paid
- Interest Received
- Issuance of Debt
- Issuance of Stock
- Net Change in Cash
- Net Income From Continuing Operations
- Net Intangibles Purchase And Sale
- Net Issuance of Debt
- Net Issuance of Preferred Stock
- Other Cash Payments from Operating Activities
- Other Cash Receipts from Operating Activities
- Other Financing
- Payments of Debt
- Payments on Behalf of Employees
- Payments to Suppliers for Goods and Services
- Purchase Of Business
- Purchase Of Investment
- Purchase Of Property, Plant, Equipment
- Receipts from Customers
- Receipts from Government Grants
- Repurchase of Stock
- Sale Of Business
- Sale Of Investment
- Sale Of Property, Plant, Equipment
- Stock Based Compensation
- Taxes Refund Paid
Technical Indicator
- 5-Day RSI
- 9-Day RSI
- 14-Day RSI
- 50-Day SMA
- 6-Month Price Index
- 6-1 Month Momentum %
- 12-1 Month Momentum %

Guardant Health GF Value

: $151.51 (As of Today)

View and export this data going back to 2018. Start your Free Trial

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2022-05-26), Guardant Health's share price is $36.49. Guardant Health's GF Value is $151.51. Therefore, Guardant Health's Price-to-GF-Value for today is 0.24.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Guardant Health is Possible Value Trap, Think Twice.

Guardant Health (NAS:GH) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Guardant Health's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	36.49	/	151.51
	=	0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guardant Health GF Value Related Terms

Thank you for viewing the detailed overview of Guardant Health's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health Business Description

Industry

Healthcare » Medical Diagnostics & Research NAICS : 621511 SIC : 8071

Comparable Companies

MIL:DIA NAS:SYNH NAS:SHC SHSE:603882 NAS:MEDP SHSE:603127 SZSE:300676 NAS:OCDX NYSE:QGEN NAS:LNTH

Traded in Other Exchanges

GH:Mexico 5GH:Germany

Address

505 Penobscot Drive, Redwood City, CA, USA, 94063

Website

https://www.guardanthealth.com

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

Executives

Talasaz Amirali	director, officer: Chairman, President and COO	18 ISABELLA AVENUE ATHERTON CA 94027
Kaul Samir	director	C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025
Meresman Stanley J	director	2071 HUNTINGTON LANE LOS ALTOS CA 94024
Svf Bluebird (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008
Svf Enterprise (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008
Sb Investment Advisers (uk) Ltd	10 percent owner	69 GROSVENOR STREET LONDON X0 W1K 3JP
Softbank Vision Fund (aiv M1) L.p.	10 percent owner	251 LITTLE FALLS DRIVE WILMINGTON DE 19808
Svf Endurance (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008
Clark Ian T	director	SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080
Eltoukhy Helmy	director, officer: Chief Executive Officer	2 BARRY LANE ATHERTON CA 94027
Bertocci Derek A	officer: Chief Financial Officer	3070 ORCHARD DRIVE SAN JOSE CA 95134
Saia John G.	officer: See Remarks	C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063
Gadde Vijaya	director	C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103
Jallal Bahija	director	120 MONUMENT CIRCLE INDIANAPOLIS IN 46204
Nishar Dipchand	director	C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043

Guardant Health Headlines

From GuruFocus

Iron Triangle Partners LP Buys DaVita Inc, NanoString Technologies Inc, UnitedHealth Group Inc, Sells Humana Inc, Horizon Therapeutics PLC, Hologic Inc

By insider 02-19-2022

Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at the American Association for Cancer Research Annual Meeting

By Business Wire 03-09-2022

Guardant Health to Participate in Upcoming Investor Conferences

By Business Wire 02-07-2022

Guardant Health Receives Regulatory Approval for Guardant360� CDx in Japan

By Business Wire 03-14-2022

Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360� Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium

By Business Wire 12-06-2021

Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors

By Business Wire 08-05-2021

Guardant Health Inc (GH) Co-CEO Amirali Talasaz Bought $10 million of Shares

By insider 11-24-2021

Eagle Health Investments LP Buys Cano Health Inc, Guardant Health Inc, Humana Inc, Sells Vertex Pharmaceuticals Inc, Seer Inc

By insider 10-21-2021

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal� Blood Test to Predict Recurrence Across Early-Stage Cancers

By Business Wire 10-05-2021

Guardant Health to Report Third Quarter Financial Results on November 4, 2021

By Business Wire 10-08-2021

Other Sources

$GH - Guardant Health, Inc. (GH) Q4 2021 Results - Earnings Call Transcript. Guardant Health Inc Gh Q4 2021 Results Earnings Call Transcript

By Seekingalpha 2022-02-23

$GH - Guardant Health, Inc. 2021 Q4 - Results - Earnings Call Presentation. Guardant Health Inc 2021 Q4 Results Earnings Call Presentation

By Seekingalpha 2022-02-24

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us 中文
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

GuruFocus Screeners

My Screeners

Value Screens

Model Portfolios

Market Data

Economic Indicators

By Country

Articles

Submit Articles

Guardant Health GF Value

Guardant Health GF Value Related Terms

Guardant Health Business Description

Guardant Health Headlines

Iron Triangle Partners LP Buys DaVita Inc, NanoString Technologies Inc, UnitedHealth Group Inc, Sells Humana Inc, Horizon Therapeutics PLC, Hologic Inc

Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at the American Association for Cancer Research Annual Meeting

Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health Receives Regulatory Approval for Guardant360� CDx in Japan

Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360� Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium

Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors

Guardant Health Inc (GH) Co-CEO Amirali Talasaz Bought $10 million of Shares

Eagle Health Investments LP Buys Cano Health Inc, Guardant Health Inc, Humana Inc, Sells Vertex Pharmaceuticals Inc, Seer Inc

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal� Blood Test to Predict Recurrence Across Early-Stage Cancers

Guardant Health to Report Third Quarter Financial Results on November 4, 2021

$GH - Guardant Health, Inc. (GH) Q4 2021 Results - Earnings Call Transcript. Guardant Health Inc Gh Q4 2021 Results Earnings Call Transcript

$GH - Guardant Health, Inc. 2021 Q4 - Results - Earnings Call Presentation. Guardant Health Inc 2021 Q4 Results Earnings Call Presentation

Why Earnings Season Could Be Great for Guardant Health (GH)

CVS Health (CVS) Q4 Earnings to Gain From COVID Vaccine Sales

Charles River (CRL) to Report Q4 Earnings: What's in Store?

Why Guardant Health Fell More Than 5% Today

Looking for Growth? Check Out These 2 Diagnostics Stocks

Guardant Health (GH) Gets a Buy Rating from Leerink Partners

Bull of the Day: Exact Sciences (EXAS)

Leerink Partners Sticks to Their Buy Rating for Guardant Health (GH)

Why Guardant Health Stock Soared Nearly 10% Higher Today

Earnings Preview: Guardant Health (GH) Q2 Earnings Expected to Decline

Why Guardant Health Stock Zoomed 10% Higher Today

What's in Store for Boston Scientific's (BSX) Q4 Earnings?

What's in Store for Quest Diagnostics (DGX) in Q4 Earnings?